OMNIA BIOSYSTEMS
Omnia Biosystems™ is a developer of an artificial intelligence-based drug target discovery platform, BioPATH AI. The BioPATH™ platform specializes in the discovery of therapeutics for challenging targets.
OMNIA BIOSYSTEMS
Social Links:
Industry:
Artificial Intelligence Biopharma Biotechnology Health Care Life Science Machine Learning Pharmaceutical Therapeutics
Founded:
2021-02-17
Website Url:
http://www.omnia.bio
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Amazon Google Google Cloud Amazon S3 CDN Netlify
Similar Organizations
Biophysical Therapeutics
Computational Biology to Design New Drugs.
Kantify
We develop AI solutions for human life with a focus on healthcare, biotech and mobility.
KYAN Therapeutics
KYAN Therapeutics is a clinical-stage AI company leveraging its proprietary technology platforms to transform the way patients are treated.
Lattice
Redefining laboratory data for Next generation biotechnology
NXT Biologics
NXT Biologics develops therapeutics for lung infections and respiratory illnesses.
OFAI
Help the logistics industry make the most accurate operational decisions with artificial intelligence
Resurgo Genetics
Resurgo Genetics is designing novel, precise interventions into living systems, using unique insights based on two decades of research.
SmartScope
SmartScope focused on bringing early stage malaria diagnoses to the masses.
Well Good
Well Good is a personalised mental health care product that prevents crisis by using data and artificial intelligence at work
Current Employees Featured
Founder
Official Site Inspections
http://www.omnia.bio
- Host name: ec2-100-28-201-155.compute-1.amazonaws.com
- IP address: 100.28.201.155
- Location: Ashburn United States
- Latitude: 39.0481
- Longitude: -77.4728
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20149
More informations about "Omnia Biosystems"
About OmniaBio - Canadian Cell and Gene Therapy …
OmniaBio is manufacturing a disease-free future through our specialized focus in cell and gene therapy. With our collaborative partnership and deep industry experience, we are using the latest technologies to drive the future of cell and …See details»
OmniaBio - LinkedIn
OmniaBio | 19,140 followers on LinkedIn. OmniaBio Inc. is bringing life-saving cell and gene therapies to patients around the world. | OmniaBio Inc., a subsidiary of CCRM, launched July 1, 2022. OmniaBio is a contract development and …See details»
Our Expertise - Cell Therapy Platform Services - OmniaBio
Defined by our collaborative and innovation-first culture, OmniaBio is a leader in cell and gene therapy (CGT) manufacturing. With deep technical expertise and experience seated within a …See details»
omnia.bio
What can you do with Omnia's Discovery Platform? Pre-clinical drug discovery is costly and plagued with inefficiencies. Omnia’s BioPATH AI™ leverages the power of enabling …See details»
OmniaBio: Positioning Ontario to lead in a global …
Apr 26, 2023 In September 2022, the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing announced it had made a $10.5 million contribution to a $34.8 million project led by OmniaBio, with …See details»
OMNIABIO: POSITIONING ONTARIO TO LEAD IN A GLOBAL
May 4, 2023 In September 2022, the industry-led organization behind Canada’s Global Innovation Cluster for Advanced Manufacturing announced it had made a $10.5 million …See details»
OmniaBio’s Impact and Future with Mitchel Sivilotti
Apr 27, 2024 Mitch Sivilotti, CEO of OmniaBio Inc., shared with CanadianSME Small Business Magazine how OmniaBio is propelling Canada to the forefront of cell and gene therapy (CGT) manufacturing. As Canada’s largest contract …See details»
OmniaBio Inc. Launch Announcement - CCRM
OmniaBio will be the first project to be funded by the Government of Ontario via the Invest Ontario Fund, receiving a loan of up to $40 million to enable the construction of a 250,000 ft2 (23,225 m2) contract development and …See details»
Funding from Ontario government launches OmniaBio Inc.
Development and manufacturing organization (CDMO) for cell and gene therapies (CGTs) – the largest facility of its kind in Canada. “We are grateful to the Government of Ontario, through …See details»
OmniaBio Announces Opening of New Commercial Manufacturing …
HAMILTON, ON, Oct. 17, 2024 /CNW/ - Today OmniaBio Inc. will announce the opening of a new North American cell and gene therapy (CGT) manufacturing and artificial intelligence (AI) …See details»
Medipost Acquires OmniaBio to Launch CDMO Business in North …
Aug 8, 2022 Medipost acquired an equity interest in OmniaBio from CCRM for cash of CAD $30 million and is investing an additional CAD $60 million in Notes into OmniaBio. Once launched, …See details»
OmniaBio - Crunchbase Company Profile & Funding
OmniaBio is a contract development and manufacturing organization producing gene-modified cell therapies and viral vectors. It supports a broad range of cell and gene therapy companies from …See details»
OmniaBio - Synapse Life Science Consortium
OmniaBio Inc., a subsidiary of Toronto-based CCRM, is a contract development and manufacturing organization (CDMO) producing gene-modified cell therapies and viral vectors, …See details»
Leadership - OmniaBio
Our Expert Team Industry Leaders Focused on Advancing Your Project Our Leadership Team Our leadership team is composed of seasoned professionals who bring a wealth of experience …See details»
OmniaBio | Ontario Bioscience Innovation Organization Job Board
Ontario Bioscience Innovation Organization, 100 College St., Suite 213, Toronto, Ontario, Canada M5G 1L5 (416) 848 6839 [email protected] (416) 848 6839 [email protected]See details»
OmniaBio brings biomanufacturing muscle to Ontario
“OmniaBio Inc. will be a game-changer for Ontario and Canada,” explains Dr. Michael May, CCRM President and CEO, and Chair of Omniabio Inc. “It will provide missing infrastructure to …See details»
Omniabio shares expansion plans with Hamilton investment …
Jun 23, 2022 Omniabio a subsidiary of CCRM, will be bringing a $580 million, 250,000 sq ft facility into the city as well as 250 highly skilled workers. Omniabio will be Canada’s first …See details»
OmniaBio expands manufacturing footprint with second Hamilton …
January 24, 2023 (Hamilton, ON) – OmniaBio Inc. has expanded its footprint by adding a new process and analytical development lab space at the McMaster University Medical Centre …See details»
OmniaBio B | Projects | Multiplex
The OmniaBio B ultra fast-tracked project is accommodating the largest cell and gene therapy Contract Development & Manufacturing Organization (CDMO) in Canada producing gene …See details»